@article {Power1015, author = {Power, Derek G. and Kemeny, Nancy E.}, title = {The role of floxuridine in metastatic liver disease}, volume = {8}, number = {5}, pages = {1015--1025}, year = {2009}, doi = {10.1158/1535-7163.MCT-08-0709}, publisher = {American Association for Cancer Research}, abstract = {Liver metastases are mainly supplied by the hepatic artery. Sustained high levels of intratumoral drug are achievable with certain drugs given via the hepatic artery. Floxuridine (FUDR) is an ideal drug for hepatic arterial infusion (HAI) due to its short half life, steep dose response curve, high total body clearance, and high hepatic extraction. HAI FUDR has consistently shown higher response rates than systemic chemotherapy alone, and some studies have shown a survival advantage. HAI FUDR in combination with systemic chemotherapy has evolved over the years and may be used in palliative, neoadjuvant, and adjuvant settings. The dramatic responses observed with HAI FUDR plus modern era systemic chemotherapy offer the possibility of resection and cure in selected patients. The high hepatic extraction of FUDR limits systemic side effects. Toxicity includes biliary and gastrointestinal ulcers. [Mol Cancer Ther 2009;8(5):1015{\textendash}25]}, issn = {1535-7163}, URL = {https://mct.aacrjournals.org/content/8/5/1015}, eprint = {https://mct.aacrjournals.org/content/8/5/1015.full.pdf}, journal = {Molecular Cancer Therapeutics} }